Skip to Main Content

Paper Details

Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer.
JCO Precis Oncol
19
2017
AR, Androgen, CDK4/6, CDK6, CDKN2A, CRPC, LnCAP cells, MYC, Metastatic Castration-Resistant Prostate Cancer, Patients, abiraterone, advanced CRPC, androgen, androgen receptor, androgens, castration-resistant prostate cancer, cell-cycle pathway genes, cyclin-dependent kinase N2A, enzalutamide, exomes, palbociclib, patient, patients, ribociclib, tumors
Author NameAffiliation
Stephanie A WankowiczDana-Farber Cancer Institute , Brigham and Women's Hospital and , Beth Israel Deaconess Medical Center, Broad Institute of Harvard and Massachusetts Institute of Technology, University of California San Diego
Glenn C GaviolaDana-Farber Cancer Institute , Brigham and Women's Hospital and , Beth Israel Deaconess Medical Center, Broad Institute of Harvard and Massachusetts Institute of Technology, University of California San Diego
Scott L CarterDana-Farber Cancer Institute , Brigham and Women's Hospital and , Beth Israel Deaconess Medical Center, Broad Institute of Harvard and Massachusetts Institute of Technology, University of California San Diego
Steven P BalkDana-Farber Cancer Institute , Brigham and Women's Hospital and , Beth Israel Deaconess Medical Center, Broad Institute of Harvard and Massachusetts Institute of Technology, University of California San Diego
William C HahnDana-Farber Cancer Institute , Brigham and Women's Hospital and , Beth Israel Deaconess Medical Center, Broad Institute of Harvard and Massachusetts Institute of Technology, University of California San Diego
William C HahnDana-Farber Cancer Institute , Brigham and Women's Hospital and , Beth Israel Deaconess Medical Center, Broad Institute of Harvard and Massachusetts Institute of Technology, University of California San Diego
Mary-Ellen TaplinDana-Farber Cancer Institute , Brigham and Women's Hospital and , Beth Israel Deaconess Medical Center, Broad Institute of Harvard and Massachusetts Institute of Technology, University of California San Diego
Eliezer M Van AllenDana-Farber Cancer Institute , Brigham and Women's Hospital and , Beth Israel Deaconess Medical Center, Broad Institute of Harvard and Massachusetts Institute of Technology, University of California San Diego
Eliezer M Van AllenDana-Farber Cancer Institute , Brigham and Women's Hospital and , Beth Israel Deaconess Medical Center, Broad Institute of Harvard and Massachusetts Institute of Technology, University of California San Diego
  • 1 - 9

Datasets

Release 1.2